FDA grants breakthrough device designation to Vesta Bladder Risk Stratify Dx

The FDA has granted Breakthrough Device Designation to Vesta Bladder Risk Stratify Dx, an artificial intelligence (AI)–enabled digital pathology assay intended to prognosticate bladder cancer risk using routine hematoxylin and eosin (H&E)–stained pathology slides, Valar Labs announced.¹

According to the company, the designation marks the first FDA Breakthrough designation issued to an AI-powered digital pathology prognostic test in bladder cancer.

Vesta Bladder Risk Stratify Dx applies proprietary AI foundation models to digitized H&E pathology slides obtained during routine clinical care to generate prognostic risk assessments. The company stated that the platform is designed to identify predictive image-based features that are not readily appreciable by human review alone.

“Vesta Bladder has been a breakthrough in biomarker driven oncology by serving a population of patients that previously had limited access to precision medicine,” said Anirudh Joshi, co-founder and chief executive officer of Valar Labs, in the company announcement.¹

The FDA Breakthrough Devices Program is intended to expedite development and review of devices that may provide more effective diagnosis or treatment for life-threatening or irreversibly debilitating conditions. The designation may facilitate prioritized interactions with regulators during the premarket review process.

Current risk stratification frameworks rely largely on conventional clinicopathologic variables such as tumor grade, stage, and size. According to Valar Labs, these models have limitations in individualized prognostication, particularly given the heterogeneous nature of non–muscle invasive bladder cancer.

“For decades, urologists have managed bladder cancer with prognostic tools that leave too many patients in the gray zone. Vesta Bladder Risk Stratify Dx gives clinicians the resolution they need to match treatment intensity to each patient's true biological risk,” said Trevor Royce, MD, chief medical officer of Valar Labs, in the press release.¹

Valar Labs stated that its underlying AI platform also supports laboratory-developed tests in prostate and pancreatic cancer through its CLIA-certified and CAP-accredited laboratory.

REFERENCE

1. Valar Labs receives FDA Breakthrough Device Designation for Vesta Bladder Risk Stratify Dx. News release. Valar Labs. May 15, 2026. Accessed May 20, 2026. https://www.businesswire.com/news/home/20260515224660/en/Valar-Labs-Receives-FDA-Breakthrough-Device-Designation-for-Vesta-Bladder-Risk-Stratify-Dx